AKESO (09926) saw its shares rise more than 5% during the morning trading session. At the time of writing, the stock was up 5.48%, trading at HK$134.8 with a turnover of HK$555 million. On the news front, Summit Therapeutics, AKESO's partner, disclosed on April 30 that the Phase 3 HARMONi-3 study for the PD-1/VEGF bispecific antibody ivonescimab did not yield the interim progression-free survival (PFS) results as planned. CITIC Securities (Hong Kong) commented that the study indicates the failure to meet expectations only reflects that ivonescimab did not significantly outperform Keytruda at the interim stage under the preset stringent criteria. The analysis emphasized that, based on experience from the HARMONi-6 trial, there is confidence that the drug will outperform Keytruda in the HARMONi-3 study in the second half of 2026 under normal and more lenient alpha allocation.